782-E Preliminary results of an in progress, first-in-human phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors

• Michael J Newman,
• Jeffery A Nieves,
• Gary B Gordon,
• Diana L Hanna,
• Angela T Alistar,
• Mohammed NAl Hallak,
• Roger J Waltzman

Affiliations

Michael J Newman

1Indaptus Therapeutics, New York, NY, USA

Jeffery A Nieves

1Indaptus Therapeutics, New York, NY, USA

Gary B Gordon

1Indaptus Therapeutics, New York, NY, USA

Diana L Hanna

2USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA

Angela T Alistar

3Atlantic Health System/Morristown Medical Center, Morristown, NJ, USA

Mohammed NAl Hallak

4Karmanos Cancer Institute, Detroit, MI, USA

Roger J Waltzman

1Indaptus Therapeutics, New York, NY, USA